Peroxisome proliferator–activated receptor γ ligands and atherosclerosis: ending the heartache
- 1 September 2000
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (5) , 629-631
- https://doi.org/10.1172/jci10909
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Insulin resistance and cardiovascular diseaseJournal of Clinical Investigation, 2000
- Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient miceJournal of Clinical Investigation, 2000
- Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in miceJournal of Clinical Investigation, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998
- Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγCell, 1998
- Lactic Acidosis in Patients with Diabetes Treated with MetforminNew England Journal of Medicine, 1998
- Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDMDiabetes, 1996
- Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.Hypertension, 1994
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988